Fibromyalgia syndrome: An overview of potential drug targets

IDrugs

Volumn 6, Issue 7, 2003, Pages 668-673

  Briley, Mike ^a   Moret, Chantal ^a  

^a NeuroBiz Consulting and Communication   (France)

Author keywords

Antidepressants; Depression; Fibromyalgia syndrome; Pain

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CYCLOBENZAPRINE; DOXEPIN; DULOXETINE; FLUOXETINE; KETAMINE; MAPROTILINE; MILNACIPRAN; NEUROKININ 1 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE AGONIST; PARACETAMOL; PAROXETINE; PIRLINDOLE; PREGABALIN; REBOXETINE; SEROTONIN 3 ANTAGONIST; SERTRALINE; TIZANIDINE; TRAMADOL; TROPISETRON; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ANXIETY; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG MEGADOSE; FIBROMYALGIA; HUMAN; LOW BACK PAIN; MENTAL DISEASE; META ANALYSIS; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PERCEPTION; POPULATION; POSTSYNAPTIC MEMBRANE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; TREATMENT FAILURE; TREATMENT INDICATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; DEPRESSION; FIBROMYALGIA; HUMANS; NOCICEPTORS; PAIN; SYNDROME;

EID: 0042165013     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. White KP, Harth M: Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep (2001) 5(4):320-329.
2. Olsen NJ, Park JH: Skeletal muscle abnormalities in patients with fibromyalgia. Am J Med Sci (1998) 315(6):351-358.
3. Bennett RM: Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc (1999) 74(4):385-398.
4. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain (2001) 91(1-2):165-175.
5. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum (1990) 33(2):160-172.
6. McCain GA: Fibromyalgia and myofascial pain. In: Textbook of Pain. 3rd Edition. Wall PD, Melzack R (Eds), Churchill Livingstone, Edinburgh, UK (1994):475-493.
7. Hawley DJ, Wolfe F: Pain, disability, and pain/disability relationships in seven rheumatic disorders: A study of 1,522 patients. J Rheumatol (1991) 18(10):1552-1557.
8. Martinez-Lavin M: Overlap of fibromyalgia with other medical conditions. Curr Pain Headache Rep (2001) 5(4):347-350.
9. Kranzler JD, Gendreau JF, Rao SG: The psychopharmacology of fibromyalgia: A drug development perspective. Psychopharmacol Bull (2002) 36(1):165-213. A recent and very complete review of the psychophamacology of fibromyalgia.
10. Rashid MH, Ueda H: Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res (2002) 953(1-2):53-62.
11. Fields HL, Heinricher MM, Mason P: Neurotransmitter in nociceptive modulatory circuits. Annu Rev Neurosci (1991) 14:219-245.
12. Herrero JF, Laird JM, Lopez-Garcia JA: Wind-up of spinal cord neurones and pain sensation: Much ado about something? Prog Neurobiol (2000) 61(2):169-203.
13. Dickenson AH: A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci (1990) 11(8):307-309.
14. Eide PK: Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain (2000) 4(1):5-15.
15. Russell IJ: Advances in fibromyalgia: Possible role for central neurochemicals. Am J Med Sci (1998) 315(6):377-384.
16. Alnigenis MN, Barland P: Fibromyalgia syndrome and serotonin. Clin Exp Rheumatol (2001) 19(2):205-210.
17. Houvenagel E, Forzy G, Leloire O, Gallois P, Hary S, Hautecoeur P, Convain L, Henniaux M, Vincent G, Dhondt JL: Cerebrospinal fluid monoamines in primary fibromyalgia. Rev Rhum Mal Osteo Articulaires (1990) 57(1):21-23.
18. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis snydrome and rheumatoid arthritis. Arthritis Rheum (1992) 35(5):550-556.
19. 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol (1993) 20(11):1986-1988.
20. Owens MJ, Nemeroff CB: Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. Clin Chem (1994) 40(2):288-295.
21. Offenbaecher M, Bondy B, De Jonge S, Glatzeder K, Kruger M, Schoeps P, Ackenheil M: Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum (1999) 42(11):2482-2488.
22. Gursoy S: Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol (2002) 21(3):194-197.
23. Schwarz MJ, Spath M, Muller-Bardoff H, Pongratz DE, Bondy B, Ackenheil M: Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett (1999) 259(3):196-198.
24. Hokfelt T, Pernow B, Wahren J: Substance P: A pioneer amongst neuropeptides. J Intern Med (2001) 249(1):27-40.
25. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum (1994) 37(11):1593-1601.
26. Bradley LA, Alberts KR, Alarcon GS, Alexander MR: Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum (1996) 39(Suppl 9):S212.
27. Neeck G, Crofford LJ: Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am (2000) 26(4):989-1002.
28. Roizenblatt S, Moldofsky H, Benedito-Silva AA, Tufik S: Alpha sleep characteristics in fibromyalgia. Arthritis Rheum (2001) 44(1):222-230.
29. Sergi M, Rizzi M, Braghiroli A, Puttini PS, Greco M, Cazzola M, Andreoli A: Periodic breathing during sleep in patients affected by fibromyalgia syndrome. Eur Respir J (1999) 14(1):203-208.
30. Tayag-Kier CE, Keenan GF, Scalzi LV, Schultz B, Elliott J, Zhao RH, Arens R: Sleep and periodic limb movement in sleep in juvenile fibromyalgia. Pediatrics (2000) 106(5):E70.
31. Burckhardt CS, Clark SR, Bennett RM: The Fibromyalgia Impact Questionnaire: Development and validation. J Rheumatol (1991) 18(5):728-733.
32. Melzack R: The McGill Pain Questionnaire: Major properties and scoring methods. Pain (1975) 1(3):277-299.
33. Lautenschlager J: Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol (2000) 113:32-36.
34. Bennett RM: Pharmacological treatment of fibromyalgia. J Funct Syndr (2001) 1:79-92. An excellent review of the treatment of fibromyalgia.
35. Wolfe F, Zhao S, Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum (2000) 43(2):378-385.
36. Russell IJ, Kamin M, Bennett R, Schnitzer T, Green J, Katz W: Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol (2000) 6:250-257.
37. Rojas-Corrales MO, Gibert-Rahola J, Mico JA: Tramadol induces antidepressant-type effects in mice. Life Sci (1998) 63(12):PL175-PL180.
38. Werner MU, Perkins FM, Holte K, Pedersen JL, Kehlet H: Effects of gabapentin in acute inflammatory pain in humans. Regional Anesth Pain Med (2001) 26(4):322-328.
39. Pfizer Inc: Pregabalin significantly improves pain in fibromyalgia patients. Press Release (2002) October 25
40. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum (1991) 34(5):552-560.
41. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, Fernandez-Rodriguez A, Hernanz-Mediano W, Gutierrez-Rubio A, De La Iglesia-Salgado JL, Garcia-Lopez A: Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial. Pain (1996) 65(2-3):221-225.
42. Gronblad M, Nykanen J, Konttinen Y, Jarvinen E, Helve T: Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol (1993) 12(2):186-191.
43. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ: The effect of zolpidem in patients with fibromyalgia: A dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol (1996) 23(3):529-533.
44. 1 (substance P) receptor antagonists: Why are they not analgesic in humans? Trends Pharmacol Sci (2000) 21:244-246.
45. 3 serotonin antagonist: A pilot study. Clin Rheumatol (2000) 19(1):6-8.
46. Arnold LM, Keck PE Jr, Welge JA: Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics (2000) 41(2):104-113. A major meta-analysis study demonstrating the activity of TCAs in fibromyalgia.
47. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL: Treatment of fibromyalgia with antidepressants: A meta-analysis. J Gen Intern Med (2000) 15(9):659-666. A second meta-analysis study demonstrating the activity of TCAs in fibromyalgia
48. Ginsberg F, Joos E, Geczy J, Bruhwyler J, Vandekerekhove K, Farnaey JP: A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Muscoloskelet Pain (1998) 6(2):5-17.
49. Ansari A: The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature. Harvard Rev Psychiatry (2000) 7(5):257-277.
50. Browne JJ: The use of reboxetine in fibromyalgia and neuropathic pain: An open, non-randomised, prospective study. 10th World Congress on Pain, San Diego, CA, USA (2002).
51. Salerno SM, Browning R, Jackson JL: The effect of antidepressant treatment on chronic back pain: A meta-analysis. Arch Intern Med (2002) 162(1):19-24.
52. Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, Waghlgren DR, Abramson I, Garfin SR: A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain (1998) 76(3):287-296.
53. Atkinson JH, Slater MA, Wahlgren DR, Williams RA, Zisook S, Pruitt SD, Epping-Jordan JE, Patterson TL, Grant I, Abramson I, Garfin SR: Effects of noradrenergic and serotonergic antidepressants on chornic low back pain intensity. Pain (1999) 83(2):137-145.
54. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatmnt of fibromyalgia. Arthritis Rheum (1996) 39(11):1852-1859.
55. Fishbain D: Evidence-based data on pain relief with antidepressants. Ann Med (2000) 32(5):305-316.
56. Briley M, Moret C: Antidepressant properties of specific serotoninnoradrenaline reuptake inhibitors. In Antidepressants: New Pharmacological Strategies. Skolnick P (Ed), Humana Press, Totowa, NJ, USA (1997):35-52.
57. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr: An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics (1998) 39(1):14-17. First publication of the activity of a SNRI in fibromyalgia.
58. Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry (2000) 57(5):503-509.
59. Nagaoka S, Ohno M, Sekiguchi A: An open clinical trial of milnacipran in fibromyalgia syndrome. Semin Arthritis Rheum (2003): manuscript submitted.
60. Cypress Bioscience Inc: Final results of milnacipran phase II clinical trial in fibromyalgia. Press Release (2003) March 21.
61. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, Kuck J, Leslie V, Masur D, Wagner M, Waid R et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics (1999) 40(1):57-63: A review of co-morbidity of psychiatric disorders and fibromyalgia.
62. Hudson JI, Hudson MS, Pilner LF, Goldenberg DL, Pope HG Jr: Fibromyalgia and major affective disorders: A controlled phenomenology and family history study. Am J Psychiatry (1985) 142(4):441-446
63. Briley M: The logical evolution toward dual action antidepressants. Drugs Focus (2001) 3(Suppl 1)5-10.
64. Sierralta F, Pinardi G, Mirandi HF: Effects of p-chlorophenylalanine and α-methyltyrosine on the antinociceptive effect of antidepressant drugs. Pharmacol Toxicol (1995) 77(4):276-280.
65. Nutt DJ: The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol (2002) 17(Suppl 1):S1-S12.
66. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montogomery S, Nelson J, Paykel E, Versiani M, Racagni G: The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol (2002) 12(5):461-475.
67. Yokogawa F, Kiuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, Hosoyamada A: An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg (2002) 95(1):163-168.
68. Kasper S, Pletan Y, Solles A, Tournoux A: Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results. Int Clin Psychopharmacol (1996) 11(Suppl 4):35-39.
69. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF: Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol (1996) 11(Suppl 4):41-46.
70. These ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry (2001) 178:234-241.
71. Russell IJ: The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am (2002) 28(2):329-342.